Some people are finding pharmacies still don't have supply of the shots, and others are having insurance coverage troubles. Here's what's going on.
Lower-income countries did not get the COVID vaccines they needed. So the World Bank and other partners tapped a South African company to cook up the (undisclosed) recipe for the Moderna mRNA vaccine.
Preliminary laboratory studies find antibodies from previous infections and vaccinations can neutralize the BA.2.86 variant. The findings bode well for new boosters on the way this fall.
A panel of advisers to the Food and Drug Administration has recommended revising the current COVID-19 vaccine so that it specifically targets omicron.
Now that official COVID emergency declarations have ended, how should people evaluate their risk of SARS-CoV-2? That's the subject of our frequently asked questions offering.
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you'll pay depends on your health insurance.
The new approach would simplify vaccination guidance so that, every fall, people would get a new shot, updated to try to match whatever variant is dominant.
The decision aims to better protect the littlest kids amid an uptick in COVID-19 cases around the country. The Centers for Disease Control and Prevention is expected to sign off soon.